Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triptorelin for Ovarian Protection in AYA Cancer Patients
NCT06513962Phase 3Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Feb 2025
- Primary completion
- Oct 2029
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of triptorelin in primary ovarian insufficiency (POI), sponsored by Children's Oncology Group. Started Feb 2025; status: recruiting.
02
Drugs
triptorelin
03
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT06513962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513962.